Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

April 15, 2026 7:20 AM EDT Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $40.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login